Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution
Authors:
- 30 October 2014
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 124 (18) , 2820-2823
Abstract
Key Points: Moderate-dose cyclophosphamide is associated with an unacceptable rate of toxicity in SAA, as in high-dose cyclophosphamide. Moderate-dose cyclophosphamide is an active regimen but is associated with a low response and does not prevent relapse or clonal evolution.Keywords
This publication has 24 references indexed in Scilit:
- Front-line immunosuppressive treatment of acquired aplastic anemiaBone Marrow Transplantation, 2012
- Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemiaBlood, 2012
- Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic AnemiaNew England Journal of Medicine, 2011
- Decreased Infection-Related Mortality and Improved Survival in Severe Aplastic Anemia in the Past Two DecadesClinical Infectious Diseases, 2011
- High-dose cyclophosphamide for severe aplastic anemia: long-term follow-upBlood, 2010
- Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized studyHaematologica, 2009
- Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazoleBone Marrow Transplantation, 2007
- Current concepts in the pathophysiology and treatment of aplastic anemiaBlood, 2006
- Reappraisal With Meta-Analysis of the Addition of Gram-Positive Prophylaxis to Fluoroquinolone in Neutropenic PatientsJournal of Clinical Oncology, 2003
- Patterns of Infection in Patients with Aplastic Anemia and the Emergence of Aspergillus As a Major Cause of DeathMedicine, 1992